cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.25934/00003696
title: Effect of Spiriva® 18 Microgram on Health-related Quality of Life and Physical Functioning in Patients With COPD and Proven Hyperinflation

description: -  Primary objective of this observational study was to gain insights into the effects of therapy with Spiriva® (tiotropium bromide) 18 microgram on the health-related quality of life and physical functioning in patients with chronic obstructive pulmonary disease (COPD) and demonstrated hyperinflation.   -  Secondary objective was to obtain safety data regarding adverse events.
DOI: 10.25934/00003694
title: A Multiple Dose Comparison of Tiotropium 18 μg Inhalation Capsules and Oxitropium MDI (2 Puffs of 100 μg) in a One-year, Open-Label, Safety and Efficacy Study in Patients With COPD

description: The objective of this study is to investigate the long-term safety of Ba 79 BR (tiotropium) powder inhalation in patients with COPD using oxitropium bromide (Tersigan) as a comparator. Secondarily, the long-term efficacy of Ba 679 BR is also investigated
DOI: 10.25934/00003693
title: A Single-blind Two-centre Trial to Compare Administration Technique, Learning Retention of the Administration Technique and Ease of Use of the HandiHaler® With Those of the Pressurised Metered Dose Inhaler (MDI) in Patients With COPD.

description: Trial to compare the administration technique for HandiHaler® vs. MDI, to compare the learning retention of the administration technique for the HandiHaler® vs. MDI and to compare the ease of use for HandiHaler® vs. MDI
DOI: 10.25934/00003692
title: The Effects of Tiotropium Therapy on Airway Diameter in Patients With COPD (a Randomized, Double-blind, Placebo-controlled, Parallel-group Study)

description: Trial to investigate the acute and chronic effect of tiotropium therapy on airway diameter in COPD patients as measured by inspiratory capacity (IC).
DOI: 10.25934/00003689
title: Effect of Tiotropium on Exercise Tolerance and Static and Dynamic Lung Volumes in COPD Patients (A Randomized Double-Blind, Placebo Controlled, Parallel Group Study)

description: Study to investigate whether tiotropium therapy can increase duration of steady-state exercise by decreasing dynamic and static lung hyperinflation in COPD patients.
DOI: 10.15468/dl.rf6kqa
title: Occurrence Download

description: A dataset containing 166 species occurrences available in GBIF matching the query:
{
 "and" : [
 "HasGeospatialIssue is false",
 "HasCoordinate is true",
 "OccurrenceStatus is Present",
 {
 "not" : {
 "BasisOfRecord" : [
 "is one of (Fossil, Living Specimen)"
 ]
 }
 },
 "TaxonKey is one of (Siphocranion nudipes (Hemsl.) Kudô)"
 ]
}

 The dataset includes 166 records from 8 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0002129-241125135418005/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.25934/00003686
title: A Phase I Open Label Dose Escalation Study of Continuous Once-daily Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumors

description: Investigation of maximum tolerated dose (MTD), safety, pharmacokinetics, pharmacodynamic parameters, and efficacy of BIBW 2992
DOI: 10.60656/7f772c563684499f
title: Custom collection of Doppler lidar wind data from Chilbolton on 9 Aug 2023
DOI: 10.25934/00005888
title: A Phase 1, Open-Label, Parallel-Group Study to Evaluate the Pharmacokinetics, Safety and Tolerability of a Single Oral Dose of 5 mg Vortioxetine in Subjects With Normal Hepatic Function or Severe Hepatic Impairment

description: The purpose of this study is to evaluate the pharmacokinetics of vortioxetine and its metabolites Lu AA34443 and Lu AA39835 following a single oral dose administration of vortioxetine 5 mg in participants with severe hepatic impairment compared to healthy participants.
DOI: 10.25934/00001324
title: 200699: A Clinical Study to Evaluate Four Doses of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component

description: The purpose of this study is to evaluate the dose-response of 4 doses of umeclidinium bromide in combination with fluticasone furoate compared with fluticasone furoate monotherapy in chronic obstructive pulmonary disease participants with an asthmatic component. The fluticasone furoate/umeclidinium bromide treatments will also be compared to the once-daily inhaled corticosteroid/long-acting beta agonist combination fluticasone furoate/vilanterol.
DOI: 10.25934/00001322
title: A 12 Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy of Umeclidinium/Vilanterol 62.5/25mcg in Subjects With COPD

description: This study is a 12-week, multicenter, randomized, double blind, parallel group, placebo-controlled study. The purpose of this study is to replicate the therapeutic benefit of UMEC/VI 62.5/25 microgram (mcg) on health-related quality of life as reflected by St. George's Respiratory Questionnaire (SGRQ) scores and symptoms as reflected by rescue medication use observed in the 6 month placebo controlled study (DB2113373). Lung function will be assessed as it provides an objective measure to support the subjective patient reported outcomes of SGRQ and rescue medication use. The study is intended to provide additional evidence to support the use of UMEC/VI for the maintenance treatment of COPD Approximately 496 subjects will be randomized from approximately 62 centers in order to ensure 422 subjects complete 12 weeks of treatment. Eligible subjects will be randomized to UMEC/VI 62.5/25mcg or placebo in a 1:1 ratio. All treatments will be administered once-daily in the morning via a Dry Powder Inhaler (DPI). There will be a total of 5 clinic visits. The total duration of study participation will be approximately 15 weeks. All subjects will be provided with albuterol/salbutamol to use as needed for the relief of COPD symptoms throughout the run-in and double-blind treatment periods.
DOI: 10.15468/dl.7vzctb
title: Occurrence Download

description: A dataset containing 5143 species occurrences available in GBIF matching the query:
{
 "and" : [
 "BasisOfRecord is one of (Observation, Human Observation, Occurrence evidence)",
 "Country is Spain",
 "OccurrenceStatus is Present",
 "TaxonKey is Acacia Mill."
 ]
}

 The dataset includes 5143 records from 22 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0002131-241125135418005/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.dk7sdv
title: Occurrence Download

description: A dataset containing 8957 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Country is China",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "OccurrenceStatus is Present",
 "TaxonKey is Garrulax perspicillatus (Gmelin, 1789)",
 "Year 1970-2024"
 ]
}

 The dataset includes 8957 records from 9 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0002130-241125135418005/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.6084/m9.figshare.27908601
title: Proactive biophysical feedback driven by adaptive mutualistic biological interactions trigger tipping point evasion in ecosystem

description: Adaptive mutualistic bio-interaction drives the ecosystem to evade critical tipping point by catalyzing biophysical feedback.
DOI: 10.6084/m9.figshare.27908601.v1
title: Proactive biophysical feedback driven by adaptive mutualistic biological interactions trigger tipping point evasion in ecosystem

description: Adaptive mutualistic bio-interaction drives the ecosystem to evade critical tipping point by catalyzing biophysical feedback.
DOI: 10.25934/00001318
title: A Double-Blind (Sponsor Unblind), Placebo Controlled, Randomised, Parallel Group Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of GSK2269557 Administered as a Dry Powder to COPD Patients and Assessment of Dose Response Using Sputum Biomarkers

description: This is a randomised, double-blind, placebo controlled, parallel group study to evaluate the safety, tolerability, pharmacokinetics and dose response of multiple doses of GSK2269557 administered as a dry powder in COPD subjects. Pharmacodynamic effects on biomarkers will also be assessed. This study will have two parts. In Part A, subjects will be randomized to active or placebo treatment in a 3:1 ratio and in Part B, to placebo or one of the six doses of active treatment in an equal ratio. A sufficient number of COPD subjects (male and female of non-child bearing potential) will be screened to ensure that approximately 30 subjects are enrolled and at least 20 evaluable subjects are obtained for Part A and approximately 35 subjects will be enrolled for Part B. In both the parts, subjects will receive study treatment once daily for 14 consecutive days. Placebo control will be included for a valid evaluation of adverse events attributable to treatment versus those independent of treatment.
DOI: 10.25934/00002909
title: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Dose-Ranging, Parallel-Group Study of PEGylated Interferon Beta-1a (BIIB017) in Healthy Volunteers

description: The primary objectives are to identify the highest safe and well-tolerated dose and frequency of BIIB017 (PEGylated Interferon Beta-1a) subcutaneous (SC), within the range of 63 to 188 mcg, when given every other week or every 4 weeks to healthy volunteers (HV).
DOI: 10.25934/00003834
title: Clinical Assessment of Fluticasone Propionate/ Salmeterol Xinafoate HFA MDI in 6-month to 4-year-old Japanese Patients With Bronchial Asthma

description: This study is a multicenter, stratified, randomized, active control, double-blinded, parallel-group comparative study with an open-label extension period. The study is designed to evaluate the efficacy and safety of FP/ SLM HFA MDI 50/25 microgram (mcg) one or two inhalation twice daily (BID) for 8 weeks in comparison with FP HFA MDI 50 mcg one or two inhalation BID, in 6-month to 4-year-old Japanese patients with bronchial asthma. The study is also designed to evaluate the safety of long-term treatment of FP/ SLM HFA MDI 50/25 mcg one or two BID for 16 weeks. The subjects meeting the eligibility criteria will enter the run-in period of 2 weeks and receive FP 50 mcg 1 or 2 inhalation bid (FP 100 or 200 mcg/day), before randomization. The subjects under 2 years of age at Visit 1 will receive only 1 inhalation bid during the run-in period. The subjects who meet the eligibility criteria for randomization will be stratified according to their age (<2 or >=2 year-old) at Visit 1 and randomized to one of the two treatment groups. The total duration of participation in the study will be 10 weeks for a comparison period completion and 27 weeks for a completion.
DOI: 10.25934/00003124
title: An Open-Label Study to Assess the Immune Response to Vaccination in Tecfidera® (BG00012)-Treated Versus Interferon-Treated Subjects With Relapsing Forms of Multiple Sclerosis.

description: Primary objective is to evaluate the immune response to vaccination with tetanus diphtheria toxoids vaccine (Td) in participants with relapsing forms of Multiple Sclerosis (MS) who have been treated with Tecfidera (BG00012) versus those treated with non pegylated interferon (IFN). Secondary objective is to evaluate the immune response to vaccination with 23-valent pneumococcal polysaccharide vaccine (PPSV23) [a mostly T cell-independent humoral response] and meningococcal polysaccharide diphtheria conjugate vaccine, quadrivalent (MCV4) [T cell-dependent neoantigen response].
DOI: 10.48597/9abr-739x
title: Meteorology at Longmont Union Reservoir

description: Measurement of Meteorology at Longmont Union Reservoir
DOI: 10.48597/gk38-6vt6
title: Measurement of Meteorology at Longmont Union Reservoir

description: Measurement of Meteorology at Longmont Union Reservoir
DOI: 10.48597/j9u8-66dg
title: Measurement of Meteorology at Longmont Union Reservoir

description: Measurement of Meteorology at Longmont Union Reservoir
DOI: 10.25934/00001311
title: 201135 : A Randomised, Double-blind, Multicenter, Parallel-group Study to Compare the Efficacy and Safety of Fluticasone Furoate (FF) 100 mcg Once Daily With Fluticasone Propionate (FP) 250 mcg Twice Daily (BD) and FP 100 mcg BD in Well-controlled Asthmatic Subjects Stepped Down From a Maintenance Therapy With RELVAR® Inhaler (FF/VI) 100/25 mcg Once-daily in Japanese Subjects

description: The primary aim of this study is to clarify the position of FF and FF/Vilanterol (VI) 100/25 micrograms (mcg) compared with existing therapies by assessing FF dosage equivalent to low to middle-dose inhaled corticosteroids (ICS). The study is divided into Run-in period, Period 1 (open-label treatment), Period 2 (double blind treatment) and Follow-up. Subjects with well controlled asthma after completing a run-in period of 4 weeks will be switched from middle-dose ICS/long acting beta 2 agonist (LABA) equivalent dose to once-daily FF/VI 100/25 mcg for an 8 weeks treatment period (Period 1). After this, subjects will be randomized in a 1:1:1 ratio to receive either FP 250 mcg twice daily, FP 100 mcg twice daily or FF 100 mcg once daily in a 12 week double blind treatment period (Period 2). There will be a 1 week Follow-up Period following completion of the double-blind treatment period, or early withdrawal from the study. Overall , the total duration of subject's participation in the study will be for 25 weeks. RELVAR is a registered trademark of the GSK group of companies.
DOI: 10.25934/00003196
title: A Phase 4, Randomized, Double-Blind Study With a Safety Extension Period to Evaluate the Effect of Aspirin on Flushing Events in Subjects With Relapsing-Remitting Multiple Sclerosis Treated With Tecfidera® (Dimethyl Fumarate) Delayed-Release Capsules

description: The primary objective of the study is to evaluate whether 150 mg enteric-coated aspirin (acetylsalicylic acid [ASA]) taken twice a day (BID) with dimethyl fumarate (DMF) administration or 75 mg enteric-coated ASA taken once daily in the morning (QAM) with DMF administration reduces the incidence and/or severity of flushing events in subjects with relapsing-remitting multiple sclerosis (RRMS) compared with ASA-placebo administered with DMF in the clinical practice setting. Secondary objectives of this study are: to evaluate the safety and tolerability of DMF administered with and without enteric-coated ASA in the clinical practice setting; to evaluate the impact of DMF administration on quality of life as measured by the Short Form 36 (SF-36®) and European Quality of Life - 5 Dimensions - 5 Levels (EQ-5D-5L) questionnaires.
DOI: 10.25934/00006918
title: Multicenter, Multi-phase, Multi-dose, Prospective, Double-blind, Placebo-controlled, Maintenance Study of Safety and Efficacy of ZS (Microporous, Fractionated, Protonated Zirconium Silicate) in Hyperkalemia.

description: It is hypothesized that ZS is more effective than placebo control (alternative hypothesis) in maintaining mean double-blind randomized maintenance phase (DBRMP) Day 8-29 serum potassium levels (3.5 - 5.0 mmol/l, inclusive) among hyperkalemic subjects in whom normokalemia was established during the open-label acute phase versus no difference between each ZS dose (highest to lowest) versus placebo control (null hypothesis).
DOI: 10.25934/00003678
title: An Exploratory, 12 Week, Randomised, Partially Double-blinded, Placebo-controlled Parallel Group Trial to Explore the Effects of Once Daily Treatments of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination or Tiotropium (Both Delivered by Respimat® Inhaler), Supervised Exercise Training and Behavior Modification on Exercise Capacity and Physical Activity in Patients With Chronic Obstructive Pulmonary Disease (COPD)

description: The primary objectives of the study are to explore the effect of treatment with orally inhaled tiotropium + olodaterol fixed dose combination with and without exercise training, and tiotropium comparing to placebo, on top of behavioural modification in improving exercise capacity in patients with COPD
DOI: 10.6084/m9.figshare.963134
title: Investigating Motorists’ Behaviors in Response to Supplementary Traffic Control Devices at Land Surveying Work Sites

description: <b>Objective:</b> Since land surveyors working alongside live traffic encounter unique safety challenges there is a great need for innovative and effective traffic control devices (TCDs) that alert motorists approaching short-term land surveying work sites. Unlike the volume of research that has been completed on traditional work zones, however, there is a limited amount of information that has been collected on how motorists respond to TCDs at land surveying work sites. This article aims to fill the void by investigating motorists’ behaviors in response to the use of 2 supplementary TCDs at land surveying work sites: portable plastic rumble strips (PPRS) and warning lights. <b>Method:</b> Extensive field tests were conducted at various land surveying work sites on 2-lane 2-way urban roadways in New Jersey. Scenarios with and without the use of the supplemental TCDs were designed. Motorists’ behavior changes were then statistically examined by using surrogate safety measures including mean speed, speed variance, speed limit compliance, and braking action. <b>Results:</b> Statistical analyses showed that the traffic speed variations did not significantly increase when the selected supplemental TCD was used; rather, motorists significantly reduced their driving speed. When warning lights and PPRS were separately deployed at the land surveying work sites the average reduction in mean speed was 6.7 and 15.2 percent, respectively. The mean speed was reduced by 19.7 percent when both of these supplementary TCDs were used. Logistic regression models developed to examine the speeding and braking behavior also showed that motorists were more likely to comply with the speed limit and increase their braking rate when the selected TCDs were used. <b>Conclusion:</b> The use of supplemental TCDs can greatly contribute to the changes in motorists’ behaviors at surveying work sites. The changes in motorists’ driving behaviors imply that the motorists reacted favorably to the deployed TCDs at the land-surveying work sites.
DOI: 10.6084/m9.figshare.963134.v3
title: Investigating Motorists’ Behaviors in Response to Supplementary Traffic Control Devices at Land Surveying Work Sites

description: <b>Objective:</b> Since land surveyors working alongside live traffic encounter unique safety challenges there is a great need for innovative and effective traffic control devices (TCDs) that alert motorists approaching short-term land surveying work sites. Unlike the volume of research that has been completed on traditional work zones, however, there is a limited amount of information that has been collected on how motorists respond to TCDs at land surveying work sites. This article aims to fill the void by investigating motorists’ behaviors in response to the use of 2 supplementary TCDs at land surveying work sites: portable plastic rumble strips (PPRS) and warning lights. <b>Method:</b> Extensive field tests were conducted at various land surveying work sites on 2-lane 2-way urban roadways in New Jersey. Scenarios with and without the use of the supplemental TCDs were designed. Motorists’ behavior changes were then statistically examined by using surrogate safety measures including mean speed, speed variance, speed limit compliance, and braking action. <b>Results:</b> Statistical analyses showed that the traffic speed variations did not significantly increase when the selected supplemental TCD was used; rather, motorists significantly reduced their driving speed. When warning lights and PPRS were separately deployed at the land surveying work sites the average reduction in mean speed was 6.7 and 15.2 percent, respectively. The mean speed was reduced by 19.7 percent when both of these supplementary TCDs were used. Logistic regression models developed to examine the speeding and braking behavior also showed that motorists were more likely to comply with the speed limit and increase their braking rate when the selected TCDs were used. <b>Conclusion:</b> The use of supplemental TCDs can greatly contribute to the changes in motorists’ behaviors at surveying work sites. The changes in motorists’ driving behaviors imply that the motorists reacted favorably to the deployed TCDs at the land-surveying work sites.
DOI: 10.6084/m9.figshare.963134.v2
title: Investigating Motorists’ Behaviors in Response to Supplementary Traffic Control Devices at Land Surveying Work Sites

description: <b>Objective:</b> Since land surveyors working alongside live traffic encounter unique safety challenges there is a great need for innovative and effective traffic control devices (TCDs) that alert motorists approaching short-term land surveying work sites. Unlike the volume of research that has been completed on traditional work zones, however, there is a limited amount of information that has been collected on how motorists respond to TCDs at land surveying work sites. This article aims to fill the void by investigating motorists’ behaviors in response to the use of 2 supplementary TCDs at land surveying work sites: portable plastic rumble strips (PPRS) and warning lights.
 
 <b>Method:</b> Extensive field tests were conducted at various land surveying work sites on 2-lane 2-way urban roadways in New Jersey. Scenarios with and without the use of the supplemental TCDs were designed. Motorists’ behavior changes were then statistically examined by using surrogate safety measures including mean speed, speed variance, speed limit compliance, and braking action.
 
 <b>Results:</b> Statistical analyses showed that the traffic speed variations did not significantly increase when the selected supplemental TCD was used; rather, motorists significantly reduced their driving speed. When warning lights and PPRS were separately deployed at the land surveying work sites the average reduction in mean speed was 6.7 and 15.2 percent, respectively. The mean speed was reduced by 19.7 percent when both of these supplementary TCDs were used. Logistic regression models developed to examine the speeding and braking behavior also showed that motorists were more likely to comply with the speed limit and increase their braking rate when the selected TCDs were used.
 
 <b>Conclusion:</b> The use of supplemental TCDs can greatly contribute to the changes in motorists’ behaviors at surveying work sites. The changes in motorists’ driving behaviors imply that the motorists reacted favorably to the deployed TCDs at the land-surveying work sites.
DOI: 10.25934/00005021
title: An Observer-blind Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Investigational Vaccine GSK2838504A When Administered to Chronic Obstructive Pulmonary Disease (COPD) Patients

description: The purpose of this Phase II study is to assess the safety, reactogenicity and immunogenicity of the investigational Non-typeable Haemophilus influenzae (NTHi) vaccine in patients with moderate and severe persistent airflow obstruction.
DOI: 10.25934/00007200
title: A Randomized, Double-Blinded, Placebo-Controlled, Single-Ascending-Dose (SAD) Study of the Safety, Tolerability, and Pharmacokinetics of BIIB061 in Healthy Adult Volunteers Including Absolute Bioavailability and Food Effect

description: The primary objective of this study is to evaluate the safety and tolerability of single doses of BIIB061 administered to healthy adult volunteers. Secondary objectives in this study population are to determine the single-dose pharmacokinetic (PK) profile and the absolute bioavailability (Fabs) of BIIB061 and to determine the effects of food intake (high-fat, high-calorie meal) on BIIB061 PK and safety.